CMV.AX - Stock quotes

Live Stock Quotes - Symbol Lookup

Ticker :	CMV.AX
Last Trade :	0.275
Last Trade At :	2/7/2012 10:52pm
Change :	0.000
Opened At :	0.270
Day Range :	0.275 - 0.270
Volume :	14315
More Details:	http://finance.yahoo.com/q?s=CMV.AX

Data delayed by 15 minutes

Detailed Chart for CMV.AX and Technical Analysis

News Headlines for CMV.AX

IMPORTANT: Bing News RSS feed has moved!
table bgColorffffbb border1pxtdGo to thenbspa hrefhttpapi.bing.comrss.aspxSourceNewsampMarketen-USampVersion2.0 ampQueryCMV.AXnew RSS pageanbspand renew your subscription.tdtable

Cytomegalovirus can be a dangerous infection: How you can help
Lives are changed every day by cytomegalovirus sy toe MEG a low vy rus or . is a common virus that affects 50 to 80 of people of all ages. It is a member of the herpes virus family and in most people it remains dormant. The Center for Disease ...

Positive data from Chimerix CMX001 Phase 2 study on disease
Chimerix Inc. a biotechnology company developing novel antiviral therapeutics today announced positive results from CMX001 Study 201 a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus disease in hematopoietic stem ...

Portage man uses art to express himself, communicate despite impairments
Kline whose artwork can be seen at the Portage Public Library was an infant when he was diagnosed with cytomegalovirus . According to the New York Department of Health is a strain of the herpes virus that affects 50 to 80 percent of ...

Ask A Trooper: Calling at the wheel could be costly for some drivers
This column is dedicated to commercial motor vehicle operators. A new law took effect Jan. 3 regarding the use of mobile phones in a and it would behoove the drivers and owners of these vehicles to pay particular attention to this new law ...

Antiviral Compound Meets Phase 2 Primary Endpoint
Chimerix Inc. announced positive results from a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus disease in hematopoietic stem cell transplant HCT recipients. In CMX001 Study 201 a double-blind placebo-controlled ...

Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus …
CMX001 is a broad spectrum Lipid-Antiviral-Conjugate completing Phase 2 clinical development for the prevention of in hematopoietic cell transplant HCT recipients. In total three abstracts related to CMX001 have been accepted for ...

Does state corruption come close to D.C.'s?
The Milwaukee Journal Sentinel now is offering JS Everywhere a new digital subscription package which gives you unlimited access to JSOnline the daily e-Edition Journal Sentinel mobile site and content previously included in Packer Insider. Also coming ...

Birth Defects New Treatment
DESLEY BLANCH Its not universally known but in the developed world the leading cause of birth defects in babies is from a common virus called cytomegalovirus or . Babies can be born with serious problems including deafness blindness cerebral palsy ...

SeraCare Launches Five New Infectious Disease Panels Including First Commercially Available Parvovirus Panel
SeraCare Life Sciences announced it has launched new infectious disease panels for HIV HBV HAV and markers and a first-of-its-kind performance panel for parvovirus B19 most commonly associated with fifth disease SeraCare Life Sciences Nasdaq ...

Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalo
Chimerix Inc. a biotechnology company developing novel antiviral therapeutics today announced that final data from CMX001 Study 201 a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus has been accepted for oral presentation ...

Live Stock Quotes